 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H13N3O |
| Molar mass | 203.245 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Feprosidnine, sold under the brand nameSydnophen, is astimulant drug which was developed in theUSSR in the 1970s.[1][2] It is structurally related to another Russian drugmesocarb but unlike mesocarb, was withdrawn earlier from production. In comparison with mesocarb it has own antidepressant activity, which makes it useful in treating depressions. Indications of feprosidnine included apathic, asthenic depressions, fatigue, apathic syndrome, narcolepsy and other similar conditions. Therapeutic range of doses: 10-50mg a day.Sydnophen has multiple mechanisms of action, the relative importance of which has not been clearly established. Effects on the body include reversible monoamine oxidase inhibition,cholinergic,[3]adrenergic,[4]opioid[5] andnitric oxide donating[6] actions, all of which may contribute to its pharmacological effects to some extent.
Feprosidnine is amesoionicsydnone imine.
A similar agent is described in theAmfetaminil article.
Base catalyzed reaction betweenacetone cyanohydrin and 40% formaldehyde solution givesglycolonitrile (1) & some acetone by-product. The amphetamine [300-62-9] (2) is then added and this is allowed to react overnight to give N-(1-phenyl-2-propylamine)-acetonitrile (3). Nitrosylation of the amino group by in situ creation of nitrous acid fromhydrochloric acid and sodium nitrite results in a 51.5% yield of feprosidnine based on the initial weight of the amine (4).
